though it was published in reasonably good journals. In some ways that was good because I wasn't constantly pitched against competition all the time, I had a complete clear run. Then my group translated this control into molecules and got well down that avenue before anybody was taking much interest. But the big shift was in 1987 when we cloned the human cdc2 gene, and suddenly it all burst upon the world. ER: Why did you choose to work on the fission yeast Schizosaccharomyces pombe rather than the more common Saccharomyces cerevisiae? PN: I wanted to take a genetic approach to the cell cycle, and yeast was the best organism to do that. I also needed to stay in the UK for domestic reasons. So the first reason was simply pragmatic-because in the UK, the best cell cycle laboratory was Murdoch Mitchison's, who worked with fission yeast. The second reason was that fission yeast divides by middle separation, which is more 'normal' than budding. ER: But with pombe being a more unusual organism, wasn't it then difficult to convince others of the more general importance of your findings? PN: It was difficult, not because it wasn't a good model but because there were relatively few people working on fission yeast. It wasn't a question of convincing people, it was more that the interested community was so small that you didn't have a natural springboard for the rest of the scientific world. The field of budding yeast was bigger so you naturally affected more people and then others were sucked in. We had to work quite a lot harder with fission yeast to be able to do that. ER: Is there a particular reason why the cell cycle field was chosen by the Nobel Prize Committee in 2001? Has there been anything specific that has now made the full impact of your discoveries evident? PN: No, but with the Physiology and Medicine prize in particular, where the science can be softer, they are cautious about making a decision too quickly. Biology is messier than physics and chemistry and they have to be really clear that it's absolutely right, and that takes There are several things. One is that we really do need to get out and show that science is an exciting activity. The problem is that science is really difficult to do well. I sometimes use a metaphor that science is like a foreign language. We would all like to read Tolstoy in Russian but to be able to really appreciate the beauty of the novel, you've first got to learn Russian and that requires a huge investment of your time and energy. And it's the same with science. You have to go through quite a lot of hard work, not all of it interesting, before you get to a point where you can truly appreciate the beauty of it. We've somehow got to communicate this beauty, the excitement of it, so that we can keep people interested while going through the difficult bits. The second is that it has got to be shown to be a decent career structure and we've got to reward people appropriately. It's a great privilege to do research, actually, but people still have to be able to live and publicly funded academic science has suffered a lot in this respect. There has been some improvement there, which is to be welcomed, but even so, scientific researchers have been undervalued by our politicians in the past and this has to be reversed. The US has a great advantage in that it acts with common mechanisms throughout a population of 250 million, but in Europe, it's just never going to be like that. But we can gain in other ways because science is a wide activity and there is a real advantage in a range of cultures approaching scientific problems. Science is done differently in the UK, Germany, France, the Mediterranean countries and Scandinavia, and we should value those cultural differences. So I think yes, it is a bit fragmented and it is a bit anarchic but we may gain something from that diversity.
ER:
The ICRF is currently merging with the other UK cancer organisation, the Cancer Research Campaign, presumably with the aim of streamlining research.
PN: I've been a strong enthusiast of the merger for several reasons. One is that we will no longer compete for the same pot of money. And secondly, we can have a national policy and strategy on all sorts of things like recruitment, training and infrastructure support, which is difficult to do with two separate organisations. The third reason is that it will be more cost-efficient, so there should be more money available for research. 'Science is done differently in the UK, Germany, France, the Mediterranean countries and Scandinavia, and we should value those cultural differences'
